((自动化翻译由路透提供，请见免责声明 ))
1月7日 - ** 远程医疗公司Hims & Hers Health的 股价盘前上涨1.23%至27.23美元
** 券商BTIG开始买入评级，目标价35美元
** 称该公司正在 "以技术和便利性颠覆医疗保健"。
** 与依赖远程就诊的纯粹远程医疗平台不同，HIMS 提供药物和治疗计划，因此该公司能更好地抵御更多患者重返就诊现场的风险 - 券商
** BTIG 估计，HIMS 超过 50% 的会员拥有个性化治疗计划。
** 预计 GLP-1 和其他肥胖症保健产品的收入增长和需求将保持强劲
** 我们 相信 GLP-1 复方制剂将继续存在 - BTIG
** HIMS提供诺和诺德 的Wegovy和Ozempic的复方制剂。
** 去年股价翻了一番多
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.